Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.53 |
| ▸ | NEU2 | Q9Y3R4 | 4/20 | 0.48 |
| ▸ | NEU4 | Q8WWR8 | 3/20 | 0.48 |
| ▸ | NEU3 | Q9UQ49 | 3/20 | 0.48 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAG | P20916 | 1/20 | 0.43 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25518923 | 1.00 | NANP (0.53) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL20122292 | 1.00 | NANP (0.53) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774745 | 0.92 | NANP (0.53) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL23640226 | 0.90 | L3MBTL1 (0.44) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774832 | 0.88 | NANP (0.50) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774790 | 0.87 | NANP (0.52) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774774 | 0.87 | NEU1 (0.52) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774810 | 0.86 | L3MBTL1 (0.41) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL26774733 | 0.85 | NEU2 (0.54) | NANPNEU2NEU4NEU3NEU1 | |
| SCHEMBL23640238 | 0.83 | NANP (0.54) | NANPNEU2NEU4NEU3NEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214607-A1 | LONG WAVELENGTH EMITTING CHEMILUMINESCENT PROBES | NEMIS TECHNOLOGIES AG (CH) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214607-A1 | LONG WAVELENGTH EMITTING CHEMILUMINESCENT PROBES | VEGFA, GUSB, NR2E3 | NANP 1677/4885NEU2 1483/4885NEU4 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.